<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875704</url>
  </required_header>
  <id_info>
    <org_study_id>OXI-SAD</org_study_id>
    <nct_id>NCT02875704</nct_id>
  </id_info>
  <brief_title>Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy</brief_title>
  <official_title>Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, markers of oxidative stress will be measured in the aqueous humour of
      stargardt disease, age related macular degeneration and diabetic retinopathy patients
      compared to controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People with Stargardt disease, age related macular degeneration (AMD) and diabetic
      retinopathy (DR) have decrease in central vision from damage to photoreceptors. One of the
      mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific
      biomarkers that can be measured in eye fluid (aqueous humor). In this study, these biomarkers
      will be assessed in people with Stargardt disease, age related macular degeneration and
      diabetic retinopathy, compared to controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous levels of oxidized adducts on protein (i.e. oxidative biomarker) in patients with stargardt disease, AMD, DR and controls</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline = Day of clinic visit for stargardt disease, AMD, DR patients and day of surgery for patients undergoing cataract surgery. No follow up is required.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Stargardt Disease</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Macular Degeneration (Age Related)</condition>
  <arm_group>
    <arm_group_label>Stargardt disease, AMD, DR patients</arm_group_label>
    <description>Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients without retinal disease who will be undergoing cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anterior Chamber (AC) Tap</intervention_name>
    <description>Aqueous Samples will be collected for measurement of biomarkers</description>
    <arm_group_label>Stargardt disease, AMD, DR patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <other_name>AC Tap</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples will only be used for measurement of biomarkers of oxidative stress
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stargardt disease, AMD, DR patients and controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent and authorization of use and disclosure of protected health
             information

          -  Age at least 18 years

          -  For the study group, patients diagnosed with Stargardt disease, age related macular
             degeneration and diabetic retinopathy by the investigators, based on clinical
             phenotype

          -  For the control group, patients with no retinal disease undergoing cataract surgery
             will be eligible.

        Exclusion Criteria:

        â€¢ None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulnar Hafiz, MD, MPH</last_name>
    <email>ghafiz1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gulnar Hafiz, MD, MPH</last_name>
      <email>ghafiz1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Campochiaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DR</keyword>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

